Regencell Bioscience Holdings Limited (RGC)
- Previous Close
5.00 - Open
5.00 - Bid --
- Ask --
- Day's Range
5.00 - 5.35 - 52 Week Range
3.16 - 30.49 - Volume
1,147 - Avg. Volume
4,209 - Market Cap (intraday)
69.619M - Beta (5Y Monthly) -0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-0.45 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
www.regencellbioscience.com12
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: RGC
Performance Overview: RGC
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGC
Valuation Measures
Market Cap
66.37M
Enterprise Value
55.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.52
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-10.04
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.59%
Return on Equity (ttm)
-41.71%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.87M
Diluted EPS (ttm)
-0.45
Balance Sheet and Cash Flow
Total Cash (mrq)
11.56M
Total Debt/Equity (mrq)
3.87%
Levered Free Cash Flow (ttm)
-2.28M